Structural Evaluations of a Selective Human STINGA230 Agonist and Its Use in Macrophage Immunotherapies

By sjmartinez • May 15, 2024

Tang Z, Zhao J, Li Y, Tomer S, Selvaraju M, Tien N, Sun D, Johnson DK, Zhen A, Li P, Wang J. Structural Evaluations of a Selective Human STING^A230 Agonist and Its Use in Macrophage Immunotherapies. ACS Med Chem Lett. 2024 Apr 12;15(5):653-658. doi: 10.1021/acsmedchemlett.4c00048. PMID: 38746895; PMCID: PMC11089548.

Tags: Hematology/Oncology, Publications

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence

Conforti F, Merlo F, Pala L, Canzian J, Tinterri B, De Pas T, Locatelli M, Dickerson JC, Cortes J, Slamon DJ, Gelber R, Bagnardi V.[...]

Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis

Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark[...]

Hyperferritinemia as a Clue to Neuroendocrine Carcinoma

Chao ES, Yoshikawa G, Qing X, Huang C. Hyperferritinemia as a Clue to Neuroendocrine Carcinoma. Cureus. 2025 Aug 13;17(8):e90020. doi: 10.7759/cureus.90020. PMID: 40951183; PMCID: PMC12431798.